Podcasts about clinical trials

Overview Evelyn Eddy Shoop PMHNP-BC joins Psychedelics Today to share her journey from Division I athlete to psychiatric mental health nurse practitioner and psilocybin research participant. In this conversation, she explains how sports injuries, OCD, and intensive treatment led her into psychiatry and eventually into a psilocybin clinical trial at Yale. Her story weaves together lived experience, clinical training, and a call for more humane systems of care and better qualitative data in psychedelic science. Early Themes: Injury, OCD, and Choosing Psychiatry Early in the episode, Evelyn Eddy Shoop PMHNP-BC describes how multiple season ending injuries in college and serious mental health stressors in her family pushed her to rethink her life path. Originally pre vet, she stepped away from veterinary medicine after realizing she could not tolerate that environment. During a semester off for surgery and mental health, she completed intensive outpatient treatment and family therapy. That time showed her how powerful psychological work could be. It also reawakened a long standing curiosity about the brain, consciousness, and human experience. This led her to switch her major to psychology and later pursue psychiatric mental health nurse practitioner training at the University of Pennsylvania. At Penn, she felt supported academically and personally. Her interest in psychedelics grew as she realized that standard OCD treatments and high dose SSRIs were not giving her the level of functioning or happiness she knew was possible. Core Insights: Psilocybin Trials, Qualitative Data, and Clinical Skepticism In the middle of the episode, Eddy shares the story of finding a psilocybin trial on ClinicalTrials.gov just as she was about to start ketamine therapy. She received placebo first, then open label psilocybin, and describes the dosing day as one of the hardest days of her life, with benefits that emerged slowly over months through integration. She uses her experience to highlight why qualitative data matters. Numbers alone cannot capture the depth of a psychedelic journey or the slow unfolding of meaning over time. She argues that subjective stories, even difficult ones, are essential for clinicians, researchers, and policymakers. Key themes include: The central role of integration support in turning a crisis level session into lasting growth How trial environments on inpatient psychiatric units can feel like prison instead of healing spaces The limits of double blind placebo trials when participants become desperate for active treatment The need for more nuanced language around psychosis and psychedelic harms Eddy also addresses skepticism in psychiatry. Many providers fear substance induced psychosis and feel uneasy with medicines whose mechanisms are not fully understood. She suggests that more lived experience stories and careful education can help bridge that gap. Later Discussion and Takeaways In the later part of the episode, Eddy and Joe discuss harm reduction, ketamine risks, and how poorly designed systems can create harm even when the medicine itself is helpful. Eddy describes being treated as "just another psych patient" once the research team left for the day, including being denied basic comforts like headache relief after an emotionally intense session. She calls for: More humane hospital and research environments Required psychedelic education in psychiatric training Honest, nonjudgmental conversations about substance use with patients Stronger public education for students and festival communities Eddy also invites listeners in Wilmington, Delaware and nearby regions to connect if they need a psychiatric mental health nurse practitioner for psychedelic related research. She hopes to bring her lived experience and clinical skills into the emerging field as psilocybin and other treatments move toward approval. Frequently Asked Questions Who is Evelyn Eddy Shoop PMHNP-BC? She is a psychiatric mental health nurse practitioner trained at the University of Pennsylvania, a former Division I athlete, and a psilocybin trial participant who now advocates for more humane and data informed psychedelic care. What did Eddy learn from her psilocybin clinical trial experience? She learned that the hardest sessions can lead to deep change when integration support is strong and when there is time to unpack insights, rather than rushing to rate symptoms on a scale. Why does she care so much about qualitative data in psychedelic research? Eddy believes that numbers cannot capture the full human impact of psychedelic therapy. Stories show how people actually live with their disorders and integrate change, which is vital for ethical practice and policy. How does she view psychedelic harms and psychosis risk? She acknowledges real risks, especially for people with certain histories, but also notes that some psychotic experiences are not distressing. She calls for more precise language, better containers, and honest harm reduction education. What role does a psychiatric nurse practitioner like Evelyn play in psychedelic care? Practitioners like Evelyn can assess risk, prescribe within legal frameworks, provide preparation and integration, and help bridge the gap between traditional psychiatry and emerging psychedelic therapies. Psychedelic care is evolving fast, and this episode shows why voices like Evelyn Eddy Shoop PMHNP-BC are essential in the current psychedelic resurgence. Her blend of lived experience, clinical training, and critical thinking points toward a future where data and story, safety and possibility, can finally grow together.

If you're interested in optimising your healthspan and lifespan, this episode is not to be missed. In the quest for longevity, the spotlight has turned to NAD+ and its precursors, NMN and NR. In this episode featuring Dr. Charles Brenner, a metabolism scientist, we dive deep into the significance of these molecules and their role in healthy aging. You'll discover that NAD+ (Nicotinamide Adenine Dinucleotide) is not just a trending topic but rather a crucial player in metabolism. Learn why Charles refers to it as the "central jewel of metabolism". In the conversation, the distinction between NMN (Nicotinamide Mononucleotide) and NR (Nicotinamide Riboside) is clarified, and you'll discover which of these molecules has the best evidence-base. You'll also find out why some popular ways to increase NAD+ are an expensive waste of time. Dr. Brenner highlights the importance of evidence-based research, citing eight randomised clinical trials demonstrating the anti-inflammatory effects of one of the NAD+ precursors in humans. One significant study focuses on peripheral artery disease (PAD), a condition affecting millions of older adults that can severely impact mobility and quality of life. Ypu'll also disciver why a simple functional test is a way better predictor of longevity than all of the espoensive epigenetic-focused Biological Age tests that are currently on the market. What You'll Learn: The Basics of NAD and Its Functions: Understand the foundational role of NAD in cellular metabolism and how it acts as a transmitter of high-energy electrons needed for energy production and cell functions. Scientific Evidence and Research: Discover the rigor behind the clinical research of NAD and its supplements, like Nicotinamide Riboside (NR), including ongoing trials and results showing anti-inflammatory properties in humans. Controversies and Misconceptions: Unpack the myths concerning longevity molecules, such as misinterpretations around resveratrol, with arguments laid out by reputable scientists like Dr. Brenner. Applications in Age-Related Diseases: Explore the potential of NR supplements in addressing conditions like peripheral artery disease and its promising though variable outcomes in treating Long COVID and neurodegenerative diseases. Critical Analysis of Clinical Trials: Learn about the importance of clinical integrity, unbiased research, and how independent laboratories contribute to credible scientific discoveries. Key Takeaways: NAD is vital for maintaining metabolic health and managing cellular stress, which is essential for healthy aging. Recent clinical trials have shown promising results for NR in reducing inflammation and improving conditions related to peripheral artery disease. There's ongoing research into NR's benefits for cognitive function, particularly its potential effects on neurodegenerative disease. Supplements should be chosen carefully, preferably ones that have been tested in clinical trials to ensure efficacy and authenticity. The conversation between Dr. Taylor and Dr. Brenner highlights the need to critically evaluate scientific claims, especially those that are widely publicised without robust evidence. Through the episode, Dr. Brenner provides deep insights into how NAD coenzymes operate within the body and why they're considered crucial for longevity research. Moreover, listeners are encouraged to discern meticulously between scientific fact and internet hype, ensuring they make informed decisions when considering supplements. The episode is a valuable resource for anyone interested in the intersection of biochemistry, aging, and healthspan science. Resources Socials: X: @CharlesMBrenner LinkedIn: https://www.linkedin.com/in/charles-brenner/ Support the Podcast If you found this conversation valuable, consider subscribing and leaving a review on your preferred podcast platform. Your feedback helps us continue to bring you insightful discussions on important health topics. 00:11 Understanding NAD+ and Longevity Molecules 01:31 Debunking Longevity Myths 03:02 The Science Behind NAD+ and Metabolism 08:46 Clinical Trials and Evidence 09:37 Peripheral Artery Disease and NAD+ 11:00 Walking Speed as a Health Indicator 13:25 Challenges with DNA Methylation Clocks 21:40 NAD+ in Metabolic Processes 23:48 The Role of NAD in DNA Repair and Cellular Health 24:09 Inflammation and Aging: The Connection 25:20 Human Longevity and Reproductive Capacity 30:02 The Hallmarks of Aging 31:11 Challenges of Living in 2025: Long COVID 31:42 Clinical Trials and NAD Supplements 34:33 The Debate on NMN vs. NR 41:58 Intravenous NAD and Its Efficacy 45:06 NAD's Role in Neurodegenerative Diseases See omnystudio.com/listener for privacy information.

Clinical trial design in nephrology is evolving. In this episode, leading experts explore why a paradigm shift is needed from traditional biomarkers to patient-centered outcomes and practical strategies for advancing trial implementation. This conversation draws on insights from the ISN Consensus Meeting on Changing Paradigms of Studies in CKD (Vancouver, Nov 22-23, 2024) where clinicians, trialists, patient partners, regulators and industry scientists came together to rethink trial endpoints, outcomes and designs. Together, they discuss how reimagining kidney trials can generate more relevant, equitable, and actionable evidence for better kidney care worldwide. ParticipantsAdeera Levin Professor of Medicine, University of British Columbia, Canada, and Past-President of the International Society of Nephrology (ISN). Dr. Levin is a global leader in kidney health research, with extensive experience in chronic kidney disease (CKD) management, clinical trials, and international health system strengthening. Jennifer Lees Senior Clinical Lecturer and Honorary Consultant Nephrologist at the University of Glasgow, UK. Dr. Lees' research focuses on improving patient outcomes in kidney disease through better trial design, biomarker evaluation, and translational approaches linking research to clinical care. Kevin Weinfurt Professor and Vice Chair of Faculty, Department of Population Health Sciences, Duke University School of Medicine, USA. Dr. Weinfurt is a behavioural scientist specializing in patient-reported outcomes (PROMs), ethical aspects of research participation, and improving the relevance of clinical trials to patients lived experiences. Hiddo J. Lambers Heerspink Professor of Clinical Trials and Personalized Medicine, University Medical Center Groningen, The Netherlands. Dr. Heerspink's work bridges pharmacology, nephrology, and precision medicine, focusing on optimizing kidney and cardiovascular outcomes through innovative clinical trial design and biomarker discovery. To read more, explore the related paper Changing Paradigms of Studies in Kidney Diseases published in Kidney International.

Dr. Rachel Gatlin entered neuroscience with curiosity and optimism. Then came chaos. She started her PhD at the University of Utah in March 2020—right as the world shut down. Her lab barely existed. Her advisor was on leave. Her project focused on isolation stress in mice, and then every human on earth became her control group. Rachel fought through supply shortages, grant freezes, and the brutal postdoc job market that treats scientists like disposable parts. When her first offer vanished under a hiring freeze, she doubled down, rewrote her plan, and won her own NIH training grant. Her story is about survival in the most literal sense—how to keep your brain intact when the system built to train you keeps collapsing.RELATED LINKS• Dr. Rachel Gatlin on LinkedIn• Dr. Gatlin's Paper Preprint• Dr. Eric Nestler on Wikipedia• News Coverage: Class of 2025 – PhD Students Redefine PrioritiesFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Join host and HRS Digital Education Committee Member Melissa Middeldorp, MPH, PhD and her guests Rod Passman, MD, FHRS, and Emma Svenberg, MD, PhD, live at HRX 2025. In this episode, we explore the AMALFI Randomized Clinical Trial, which evaluated whether remote, wearable-based screening can effectively detect asymptomatic atrial fibrillation in high-risk adults. The discussion breaks down the study design, key findings, and implications for population-level AF screening strategies. It also examines how emerging digital health tools may integrate into routine cardiovascular prevention.    Learning Objectives Describe the design, patient population, and primary outcomes of the AMALFI Randomized Clinical Trial. Evaluate the effectiveness of remote wearable monitoring compared with usual care for detecting asymptomatic atrial fibrillation. Discuss the potential clinical and health-system implications of implementing large-scale remote AF screening in high-risk populations.   Article Authors Rohan Wijesurendra, DPhil, Guilherme Pessoa-Amorim, DPhil, Georgina Buck, MSc,Charlie Harper, DPhil, Richard Bulbulia, MD, Alison Offer, PhD, Nicholas R. Jones, DPhil, Christine A'Court, MA, Rijo Kurien, MSc, Karen Taylor, MSc, Barbara Casadei, DPhil, Louise Bowman, MD.   Podcast Contributors Melissa E. Middeldorp, MPH, PhD Rod S. Passman, MD, FHRS Emma Svennberg, MD, PhD   Article for Discussion  

If you've been looking for a smart, scalable, low-lift revenue stream to add to your pharmacy—this session is absolutely worth your time. Independent pharmacies are perfectly positioned to support clinical trial recruitment, yet most have never been invited to participate. SiteLabs is changing that. In this session, Paige and Darren break down exactly how you can plug into a nationwide colorectal cancer clinical trial and earn $140–$200 per qualified patient enrollment, all while improving patient care in your community.   **Show Notes:** 1. **Introduction** [0:00] 2. **Overview of Site Labs and Clinical Trial Program** [6:30] 3. **Details of the Clinical Trial Program** [15:50] 4. **Q&A and Additional Information* [21:57]     ----- #### **Becoming a Badass Pharmacy Owner Podcast is a Proud to be Apart of the Pharmacy Podcast Network**

EPISODE DESCRIPTIONBefore she was raising millions to preserve fertility for cancer patients, Tracy Weiss was filming reenactments in her apartment for the Maury Povich Show using her grandmother's china. Her origin story includes Jerry Springer, cervical cancer, and a full-body allergic reaction to bullshit. Now, she's Executive Director of The Chick Mission, where she weaponizes sarcasm, spreadsheets, and the rage of every woman who's ever been told “you're fine” while actively bleeding out in a one-stall office bathroom.We get into all of it. The diagnosis. The misdiagnosis. The second opinion that saved her life. Why fertility preservation is still a luxury item. Why half of oncologists still don't mention it. And what it takes to turn permission to be pissed into a platform that actually pays for women's futures.This episode is blunt, hilarious, and very Jewish. There's chopped liver, Carrie Bradshaw slander, and more than one “fuck you” to the status quo. You've been warned.RELATED LINKSThe Chick MissionTracy Weiss on LinkedInFertility Preservation Interview (Dr. Aimee Podcast)Tracy's Story in Authority MagazineNBC DFW FeatureStork'd Podcast EpisodeNuDetroit ProfileChick Mission 2024 Gala RecapFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

We open with community member MiMi, who shares her experience participating in an Eli Lilly Retatrutide clinical trial, offering a rare, real-world look at this next-generation triple-agonist research. From there, we dive into how menopause and perimenopause reshape metabolism with insight from Dr. Komal Patil-Sisodia, an endocrinologist, obesity-medicine specialist, and midlife menopause expert. We explore how HRT and GLP-1 medications support symptoms, weight, and long-term health, what early research suggests about combining them, and why bone density, TMJ, and diabetes risk all matter in midlife care.Follow Mimimimi_in_australiaFollow Dr. Patil drpatilsisodiaSend us Fan Mail! GetClaimable.com/PlusSideZ to appeal your GLP-1 Insurance Denails and use code PlusSideZ to save! Support the showKim Carlos, Executive Producer TikTok https://www.tiktok.com/@dmfkim?is_from_webapp=1&sender_device=pc Instagram https://www.instagram.com/dmfkimonmounjaro?igsh=aDF6dnlmbHBoYmJn&utm_source=qr Kat Carter, Associate Producer TikTok https://www.tiktok.com/@katcarter7?is_from_webapp=1&sender_device=pc Instagram https://www.instagram.com/mrskatcarter?utm_source=ig_web_button_share_sheet&igsh=ZDNlZDc0MzIxNw==

BrainStorm wants to hear from you! Send us a text.The quest to speed up clinical trials is personal for John Dwyer, CEO of the Global Alzheimer's Platform (GAP). A long-time UsA2 advocate, he's been motivated by the generations of family members lost to Alzheimer's and Parkinson's disease. Dwyer shares with BrainStorm host Meryl Comer the critical challenges of NIH funding cuts by the Trump Administration, forcing many trial sites to shut down at a time of new FDA-cleared blood tests for early diagnosis.  Dwyer highlights GAP's innovations in improving the participant experience through streamlining visits, personalized feedback, and bringing mobile trials directly to small communities. This must listen episode reinforces clinical trial participation as a valuable care option while advancing research for millions affected by Alzheimer's and related dementias. This episode of BrainStorm is sponsored by Johnson & JohnsonSupport the show

Dr. Jeanine Cook-Garard and Pandora Groth learn about clinical trials, especially concerning phase 1, or early-stage trial in oncology.  They speak with Dr. Geraldine O'Sullivan Coyne, who was recently named to lead The Northwell Cancer Institute START Center for Cancer Research - the first site in New York, expanding the community-based early-phase oncology research network.  Northwell's START unit is located at the R.J. Zuckerberg Cancer Center in New Hyde Park. Dr. O'Sullivan Coyne joins Northwell Health after two years as a clinical investigator at START Dublin in Ireland, and 10 years at the National Cancer Institute in Maryland.

Process innovation in the pharmaceutical industry is never easy, but its best chance of success comes when companies come together to work on big problems – especially when they bring in regulators and other stakeholders.   In today's episode of the pharmaphorum podcast, host Jonah Comstock speaks with Rob DiCicco, vice president of portfolio management at TransCelerate Biopharma, a membership organisation where big pharma companies work together to innovate around the discovery, development, and manufacturing of new drugs.   DiCicco gives an update on TransCelerate's work with pragmatic trials and the group's meetings last year with the FDA. He discusses what pragmatic trials are and how they can improve the efficiency of clinical research, as well as describing the work that was done at the meeting last year and the report that's come out of it.   He also gets into next steps, how the new administration has and hasn't affected the work TransCelerate is doing with the FDA, and the role TransCelerate plays in taking these recommendation and putting them into practice.   Tune in to learn how the pharma industry is working together to change the way clinical trials are done.

The FDA belatedly liberates women's hormone replacement; Beta-blockers now deemed passé for routine heart attack aftercare; After most breast cancer surgery, adjuvant radiation brings no survival benefits; Can you drink caffeinated coffee if you have atrial fibrillation? Ignore frequent falls without attention to balance and stability training at your peril; Is it reasonable to contemplate a knee replacement surgery at 88? 

BUFFALO, NY – November 17, 2025 – A new #research perspective was #published in Oncotarget (Volume 16) on November 14, 2025, titled “A personal perspective of patient-centred clinical trials.” In this perspective, led by corresponding author Jia Liu of The Kinghorn Cancer Centre, St Vincent's Hospital, the University of New South Wales, and the Garvan Institute of Medical Research, three early-phase clinical trial participants — Trevor Tyne, Elizabeth Ivimey, and Leanne Duggan — reflect on their personal experiences with experimental cancer treatments. Their stories offer a unique perspective on the patient journey through early-phase trials and emphasize the need to design clinical research that prioritizes patients' needs, dignity, and lived realities. The authors highlight both the life-changing opportunities that trials can provide and the systemic barriers that still prevent many patients from participating. This perspective captures a turning point in how early-phase trials are viewed. Once considered a last resort, these trials are now increasingly offered earlier in treatment, especially with the rise of biomarker-guided therapies. In this context, the patient experience has become critical. The authors outline key benefits of participation, including access to novel therapies, ongoing medical monitoring, emotional support, and a strong sense of purpose in contributing to future medical advancements. However, they also point out significant challenges, such as restrictive eligibility criteria, high financial and logistical burdens, and communication gaps between patients and trial staff. “While no trial guarantees success, the level of support, access to innovative therapies, and sense of contribution to medical progress can be profoundly meaningful.” Each narrative provides insight into the clinical trial experience. One patient explains how living with a visual impairment required tailored accessibility support throughout the trial process Another shares how genomic testing led to targeted treatment after standard options failed. Despite their different diagnoses and circumstances, all three stories reflect resilience, hope, and a shared call for trial designs that better reflect the realities of diverse patients. To address these issues, the authors propose a number of improvements to trial design and delivery. These include expanding eligibility criteria, offering financial and logistical assistance, improving communication training for research staff, and introducing dedicated trial navigators to help guide patients through complex processes. They also focus on the importance of involving patient advocates in trial design and ensuring smoother transitions for patients moving between treatment centers. While early-phase trials focus on safety and effectiveness, the authors argue they must also be guided by core values like ethics and patient empowerment. This perspective serves as a reminder that the future of cancer research depends not only on scientific innovation, but on an honest partnership between patients and the research community. By sharing these real-world experiences, the article encourages a broader conversation about how to make clinical trials more responsive to the people they are designed to serve. DOI - https://doi.org/10.18632/oncotarget.28776 Correspondence to - Jia Liu - jia.liu@svha.org.au Abstract video - https://www.youtube.com/watch?v=2CCGN78n8ug To learn more about Oncotarget, visit https://www.oncotarget.com: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

The Spiders briefly discuss Clinical Trials, Violet Lucca's scholarly analysis of David Cronenberg's filmography, focusing primarily on the downsides of theory-oriented analysis, then go into more depth on the relationship between Cronenberg's new film The Shrouds and his earlier work Naked Lunch.

Featuring perspectives from Dr Jeremy S Abramson and Dr Manali Kamdar, including the following topics:  Introduction: About This Program (0:00) Overview of Chimeric Antigen Receptor (CAR) T-Cell Therapy (3:10) Potential Treatment Benefits of CAR T-Cell Therapy (10:35) CRS (Cytokine Release Syndrome) and ICANS (Immune Effector Cell-Associated Neurotoxicity Syndrome) (34:32) Finding Information About CAR T; Clinical Trials (42:17) Financial Issues; Risk of Infection (48:11) Coping with Anxiety; Healing and Moving On (55:17) Educational and presenter information

The Foundation funded preclinical studies for the approach and launched Opus.

Biochemist Lingyin Li survived breast cancer at just 30 and now works to harness the human immune system to fight cancers that have long evaded treatment. T cells, she says, are powerful cancer killers, but they can be oblivious. She and her lab colleagues have discovered a masking enzyme that squelches the immune system's “danger signals” and are now developing drugs to block that enzyme. She likens her work to an arms race between cancer and immunotherapy. “The cancers are not getting smarter, but we are,” Li tells host Russ Altman on this episode of Stanford Engineering's The Future of Everything podcast.Have a question for Russ? Send it our way in writing or via voice memo, and it might be featured on an upcoming episode. Please introduce yourself, let us know where you're listening from, and share your question. You can send questions to thefutureofeverything@stanford.edu.Episode Reference Links:Stanford Profile: Lingyin LiConnect With Us:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads / Bluesky / MastodonConnect with School of Engineering >>> Twitter/X / Instagram / LinkedIn / FacebookChapters:(00:00:00) IntroductionRuss Altman introduces guest Lingyin Li, a professor of biochemistry at Stanford University.(00:03:38) Research MotivationLingyin explains how her breast cancer diagnosis inspired her research.(00:04:31) How T-Cells WorkT-cell mechanisms and why they struggle to reach solid tumors.(00:05:38) Immune System OverviewInnate and adaptive immunity and how mutations make cancer recognizable.(00:07:28) Awakening the Immune SystemEfforts to stimulate innate immune cells to detect and expose tumors.(00:10:54) The Cancer SignalDiscovery of cancer-derived DNA signals that alert the immune system.(00:13:01) Cancer's Evasion MechanismHow tumors destroy immune signals to hide from detection.(00:14:26) ENPP1 EnzymeIdentification of ENPP1 as the enzyme enabling immune evasion.(00:15:22) Balancing Immunity and SafetyRole of ENPP1 in autoimmunity and the challenge of targeting it safely.(00:19:30) ENPP1 InhibitorsDevelopment of molecules to block ENPP1 and enhance immune signaling.(00:24:55) Preclinical FindingsThe promising results against aggressive solid tumors in animal studies(00:28:05) From Lab to ClinicThe progress toward FDA approval and preparation for human testing.(00:31:04) Future In a MinuteRapid-fire Q&A: innovation, collaboration, and the outlook for cancer treatment.(00:33:14) Conclusion Connect With Us:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads / Bluesky / MastodonConnect with School of Engineering >>>Twitter/X / Instagram / LinkedIn / Facebook Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Clinical trials turn scientific discoveries into real options for patients and volunteers, advancing care while safeguarding participants. Sheldon Morris, M.D., M.P.H., explains how independent oversight, core ethical principles, and stepwise phases evaluate safety and benefit, and clarifies participants' rights and responsibilities. Sandip Patel, M.D., F.A.S.C.O., highlights how carefully designed studies open access to promising cell and gene-based approaches while balancing risks and benefits. Robert A.J. Signer, Ph.D., underscores why participation—including consenting to share samples and data—helps researchers understand disease and accelerate better treatments. Morris, Patel, and Signer point audiences to practical ways to locate studies through registries and national databases, discuss what costs are typically covered, and advise asking questions about study design and safety. They also caution against unproven “stem cell tourism” and emphasize informed decisions. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40438]

Clinical trials turn scientific discoveries into real options for patients and volunteers, advancing care while safeguarding participants. Sheldon Morris, M.D., M.P.H., explains how independent oversight, core ethical principles, and stepwise phases evaluate safety and benefit, and clarifies participants' rights and responsibilities. Sandip Patel, M.D., F.A.S.C.O., highlights how carefully designed studies open access to promising cell and gene-based approaches while balancing risks and benefits. Robert A.J. Signer, Ph.D., underscores why participation—including consenting to share samples and data—helps researchers understand disease and accelerate better treatments. Morris, Patel, and Signer point audiences to practical ways to locate studies through registries and national databases, discuss what costs are typically covered, and advise asking questions about study design and safety. They also caution against unproven “stem cell tourism” and emphasize informed decisions. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40438]

Clinical trials turn scientific discoveries into real options for patients and volunteers, advancing care while safeguarding participants. Sheldon Morris, M.D., M.P.H., explains how independent oversight, core ethical principles, and stepwise phases evaluate safety and benefit, and clarifies participants' rights and responsibilities. Sandip Patel, M.D., F.A.S.C.O., highlights how carefully designed studies open access to promising cell and gene-based approaches while balancing risks and benefits. Robert A.J. Signer, Ph.D., underscores why participation—including consenting to share samples and data—helps researchers understand disease and accelerate better treatments. Morris, Patel, and Signer point audiences to practical ways to locate studies through registries and national databases, discuss what costs are typically covered, and advise asking questions about study design and safety. They also caution against unproven “stem cell tourism” and emphasize informed decisions. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40438]

Clinical trials turn scientific discoveries into real options for patients and volunteers, advancing care while safeguarding participants. Sheldon Morris, M.D., M.P.H., explains how independent oversight, core ethical principles, and stepwise phases evaluate safety and benefit, and clarifies participants' rights and responsibilities. Sandip Patel, M.D., F.A.S.C.O., highlights how carefully designed studies open access to promising cell and gene-based approaches while balancing risks and benefits. Robert A.J. Signer, Ph.D., underscores why participation—including consenting to share samples and data—helps researchers understand disease and accelerate better treatments. Morris, Patel, and Signer point audiences to practical ways to locate studies through registries and national databases, discuss what costs are typically covered, and advise asking questions about study design and safety. They also caution against unproven “stem cell tourism” and emphasize informed decisions. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40438]

Clinical trials turn scientific discoveries into real options for patients and volunteers, advancing care while safeguarding participants. Sheldon Morris, M.D., M.P.H., explains how independent oversight, core ethical principles, and stepwise phases evaluate safety and benefit, and clarifies participants' rights and responsibilities. Sandip Patel, M.D., F.A.S.C.O., highlights how carefully designed studies open access to promising cell and gene-based approaches while balancing risks and benefits. Robert A.J. Signer, Ph.D., underscores why participation—including consenting to share samples and data—helps researchers understand disease and accelerate better treatments. Morris, Patel, and Signer point audiences to practical ways to locate studies through registries and national databases, discuss what costs are typically covered, and advise asking questions about study design and safety. They also caution against unproven “stem cell tourism” and emphasize informed decisions. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40438]

Clinical trials turn scientific discoveries into real options for patients and volunteers, advancing care while safeguarding participants. Sheldon Morris, M.D., M.P.H., explains how independent oversight, core ethical principles, and stepwise phases evaluate safety and benefit, and clarifies participants' rights and responsibilities. Sandip Patel, M.D., F.A.S.C.O., highlights how carefully designed studies open access to promising cell and gene-based approaches while balancing risks and benefits. Robert A.J. Signer, Ph.D., underscores why participation—including consenting to share samples and data—helps researchers understand disease and accelerate better treatments. Morris, Patel, and Signer point audiences to practical ways to locate studies through registries and national databases, discuss what costs are typically covered, and advise asking questions about study design and safety. They also caution against unproven “stem cell tourism” and emphasize informed decisions. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40438]

In this Huberman Lab Essentials episode, my guest is Dr. Jack Feldman, PhD, a Distinguished Professor of Neurobiology at the University of California, Los Angeles, and a leading expert in the science of breathing. We explain the mechanics of breathing and the neural circuits that generate and regulate our breathing rhythm. We also discuss how breathing patterns profoundly influence mental states, including their role in reducing anxiety and enhancing emotional resilience. Dr. Feldman also shares practical tools, such as box breathing for daily performance and magnesium L-threonate supplementation to support cognitive health and longevity. Read the episode show notes at hubermanlab.com. Thank you to our sponsors AGZ by AG1: https://drinkagz.com/huberman Mateina: https://drinkmateina.com/huberman Eight Sleep: https://eightsleep.com/huberman Timestamps 00:00:00 Jack Feldman 00:00:23 Breathing Mechanics, Diaphragm; Pre-Bötzinger Complex & Breath Initiation 00:03:25 Nose vs Mouth Breathing 00:04:23 Sponsor: Mateina 00:05:24 Active Expiration & Brain; Retrotrapezoid Nucleus 00:08:32 Diaphragm & Evolution; Lung Surface Area & Alveoli, Oxygen Exchange 00:12:56 Diaphragmatic vs Non-Diaphragmatic Breathing 00:14:23 Physiological Sighs: Frequency & Function; Polio & Ventilators 00:18:21 Sponsor: AGZ by AG1 00:19:52 Drug Overdose, Death & Gasps 00:21:38 Meditation, Slow Breathing & Fear Conditioning Study 00:25:28 Mechanistic Science in Breathwork Validation; Breath Practice & Reduced Fear 00:27:21 Breathing & Emotional/Cognitive State, Olfaction, Vagus Nerve 00:29:44 Carbon Dioxide, Hyperventilation & Anxiety 00:31:21 Sponsor: Eight Sleep 00:32:47 Breathing, Emotion & Autonomic Processes Coordination; Depression & Breath Practices 00:36:43 Tool: Breathwork Practices, Box Breathing, Tummo, Wim Hof 00:38:46 Magnesium L-Threonate & Cognitive Enhancement; Compound Refinement 00:44:28 Clinical Trial, Magnesium L-Threonate & Cognitive Improvements; Dose, Sleep 00:48:28 Acknowledgements Disclaimer & Disclosures Learn more about your ad choices. Visit megaphone.fm/adchoices

Love the episode? Send us a text!Inside the VIKTORIA-1 trial with Dr. Rachel LaymanWhat the New Genitolasib Data Mean for ER+ / HER2- Metastatic Breast CancerIn this episode of Breast Cancer Conversations, Laura sits down with Dr. Rachel Layman, breast medical oncologist at MD Anderson Cancer Center, to unpack what's new in ER-positive, HER2-negative metastatic breast cancer—and why clinical trials are not just a last-ditch option.Dr. Layman walks us through the VIKTORIA-1 trial, a phase III study of a new IV drug (genitolasib, “G” for short) that targets the PAM pathway, which cancer cells often use to grow and outsmart standard hormone therapy. She explains, in plain language, what PIC3CA mutations are, what “wild-type” means, and why this trial is so exciting even for people without a PIC3CA mutation.You'll hear:Why ER-positive breast cancer is the most common subtype—and still a major driver of metastatic diseaseHow clinical trials are designed, and why they're often most powerful earlier in treatment (not only when “nothing else is left”)A clear explanation of the VIKTORIA-1 study design: who was eligible, how the drug is given, and what the results showedWhat “progression-free survival” means and how adding “G” changed the numbers compared to standard therapy aloneHonest talk about side effects (mouth sores, rash, blood sugar changes), and how teams are preventing and managing themHow patients can look up trials like VIKTORIA-1 and VIKTORIA-2 on ClinicalTrials.gov and bring these conversations back to their own oncologistsWhether you're living with ER-positive metastatic breast cancer, supporting someone who is, or simply trying to understand the rapidly evolving science, this episode offers both education and hope.Support the showLatest News: Become a Breast Cancer Conversations+ Member! Sign Up Now. Join our Mailing List - New content drops every Monday!

Can your chatbot tell when you're spiraling, or does it just play along?In this episode of Your AI Injection, host Deep Dhillon sits down with Dr. Grin Lord, clinical psychologist and Founder/CEO of mpathic, to explore what happens when empathic AI meets real human vulnerability. Grin explains how a single 15-minute session of empathic listening in an ER setting led to massive drops in repeat drunk-driving incidents and billions in healthcare savings, and why that same science now underpins AI models that analyze clinician–patient conversations. The two dig into how mpathic trains and validates models that can flag suicide risk, psychosis, and protocol deviations in high-stakes clinical trials, all while keeping a human in the loop. They also unpack a looming dilemma: as foundation models become eerily “good listeners,” will people prefer bots to friends and therapists? What harms emerge when AI politely reflects back someone's delusions? Tune in to hear how psychologists are reshaping AI safety, and why your favorite assistant may soon be better at detecting crises than your closest human relationships.Learn more about Grin here: https://www.linkedin.com/in/grinlord/and mpathic here: https://www.mpathic.aiCheck out our related episodes:Can Humanoid Robots Save Us from Loneliness? The Promise and Peril of Empathetic AI with Niv Sundaram of Machani RoboticsIs AI the Missing Ingredient for Curbing Cravings? Emotional Eating Meets Machine Learning with Dr. Sera LavelleCan AI Spot Diseases Your Doctor Might Miss? The Machine That Never Gets Tired with RJ Kedziora of Estenda Solutions

Join host and Digital Education Committee Member Sandeep A Saha, MD, MS, FHRS for this lively discussion with his colleagues Charles A. Henrikson, MD, MPH, FHRS and Arun R. Mahankali Sridhar, MBBS, MPH, FACC. About this Article: In patients with symptomatic premature ventricular complexes (PVCs) refractory to medical therapy, non-invasive low-level tragus stimulation of the auricular branch of the vagus nerve significantly reduced median PVC burden compared to sham stimulation (median reduction ~13.4% vs ~8.6%; P = 0.021). The findings suggest that autonomic neuromodulation via transcutaneous vagal stimulation may offer a novel adjunctive therapy for frequent PVCs, although further larger trials are needed to evaluate long-term outcomes. Learning Objectives Describe the rationale and mechanism by which transcutaneous vagus nerve stimulation (tVNS) may modulate autonomic tone and reduce premature ventricular contractions. Summarize the design, methods, and key outcomes of the NoVa-PVC randomized crossover trial evaluating tVNS for symptomatic PVC reduction. Evaluate the clinical implications, limitations, and potential future applications of noninvasive neuromodulation as a therapeutic approach for ventricular arrhythmias. Article Authors Stefanos Zafeiropoulos MD, MBA, Kristie Coleman MPH, RN, Jonathan Kogan,Dimitrios Varrias MD, Jonas Leavitt BS, Alexandra Bekiaridou MD, Theodoros Zanos PhD, Stavros Zanos PhD, MD, Stavros Stavrakis PhD, MD, Stavros Mountantonakis MD, MBA  Podcast Contributors Sandeep A Saha, MD, MS, FHRS Charles A. Henrikson, MD, MPH, FHRS Arun R. Mahankali Sridhar, MBBS, MPH, FACC  All relevant financial relationships have been mitigated. Host Disclosure(s): S. Saha •Speaking/Teaching/Consulting: Medtronic   ​Contributor Disclosure(s):    C. Henrikson •Honoraria/Speaking/Teaching/Consulting: American College of Cardiology A. Sridhar •Nothing to disclose.   Staff Disclosure(s) (note: HRS staff are NOT in control of educational content. Disclosures are provided solely for full transparency to the learner): S. Sailor: No relevant financial relationships with ineligible companies to disclose.

What does it really take to challenge the status quo, fight for truth, and defend your values in a system built to silence dissent?For Aaron Siri, attorney and advocate, it began in courtrooms and regulatory filings, standing up for parental rights, informed consent, and transparent systems, even when the odds were stacked against him. Today, he navigates litigation, policy, and public trust in one of the most contentious debates of our time: vaccines.In this episode of Common Denominator, we unpack Aaron's journey from legal underdog to vocal defender of transparency, how he analyzes systems most ignore, and why courage isn't loud, it's consistent.In this episode, you'll learn:- What it looks like when regulatory systems prioritize power over process- Why informed consent and transparency matter more today than ever- The mindset shifts required to challenge conventional wisdom and speak truth to power- How to stay true to your values when pressure to conform is constant- What freedom of speech really means when you're up against the establishmentLike this episode? Leave a review here: https://ratethispodcast.com/commondenominatorLearn more about Aaron Siri: Siri & Glimstad Law Firm: https://www.sirillp.com/aaron-siri/Book: "Vaccines, Amen: The Religion of Vaccines" https://www.amazon.com/stores/author/B0FQ4JMV3M

Send us a textDr. Evan Loh joins Dr. Michael Koren to discuss Dr. Loh's journey through the medical profession. Dr. Loh moved from doing lab work in medical school to patient care in the academic sphere and into the pharmaceutical world of research. Dr. Loh and Dr. Koren discuss the core differences between bedside physican work and research, including in time spent with patients, physician incentives, and the treatment that results. Through it all the doctors find a simple axiom: all medicine is about patients at the end of the day.Be a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on Apple PodcastsWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramX (Formerly Twitter)LinkedInWant to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

Pre-Order The Forever Strong PLAYBOOK and receive exclusive bonuses: https://drgabriellelyon.com/playbook/Want ad-free episodes, exclusives and access to community Q&As? Subscribe to Forever Strong Insider: https://foreverstrong.supercast.comIn this fascinating episode, Dr. Gabrielle Lyon talks with neuroscientist Dr. Ben Rein, PhD (author of Why Brains Need Friends), about the science of social connection, emotion, and cognitive health. Dr. Rein, an expert in neurobiology and psychedelic research, reveals the cutting-edge studies that explain why loneliness is as damaging as smoking and how our digital world is affecting our brain's ability to connect.They discuss the neurochemistry of love, the controversial use of MDMA in therapy, and whether AI can ever truly replace human intimacy. This conversation provides an essential look at the biological drivers of happiness, performance, and long-term brain health.Chapter Markers:0:00 - MDMA (Molly): The History & Therapeutic Benefits 5:59 - The Legal Status of MDMA for PTSD 6:44 - The Safety and Effectiveness of MDMA in Clinical Trials 8:29 - PTSD (The Amygdala Alarm) 9:41 - How MDMA Soothes the Amygdala to Access Memory 11:42 - Is There an Alternative to MDMA? (Ketamine's Mechanism) 13:16 - Ketamine and Neuroplasticity for Depression 15:48 - Botox and Empathy: 18:12 - The Problem of Volume: How Screens Depersonalize Interaction 19:48 - The Virtual Disengagement Hypothesis Explained 25:00 - Defining Cognitive and Emotional Empathy 29:43 - MDMA's Link to Serotonin & Social Reward 31:04 - Do SSRIs Have Pro-Social Effects? 36:10 - The Science of Likability and "Easy to Read" Faces 40:10 - Top 3 Ways to Be More Likable49:49 - The Likability Gap: Why You Underestimate How Well-Liked You Are 56:59 - The Neurobiology of Oxytocin, Dopamine, and Serotonin1:09:23 - The Goldilocks Zone of Empathy 1:15:58 - Narcolepsy 1:18:16 - Alcohol: Why the Neurotoxin is Bad for Brain Health 1:21:47 - Exercise and Neurogenesis1:22:27 - Sex, Orgasm, and Oxytocin Release 1:25:06 - Oxytocin During Childbirth Who is Ben Rein:Dr. Ben Rein is an award-winning neuroscientist and Chief Science Officer of the Mind Science Foundation, where he supports early-career researchers in neuroscience. He earned his PhD from SUNY Buffalo and completed postdoctoral training at Stanford University, publishing over 20 peer-reviewed papers on autism, empathy, MDMA, and digital behavior. Recognized by the NIH, the Society for Neuroscience, and Sigma Xi, he also serves as a scientific advisor to more than 20 organizations. With over one million followers and 75 million video views, Dr. Rein is celebrated for making neuroscience accessible to the public and has been featured by outlets such as Good Morning America, ABC News, and PopularMechanics.Thank you to our sponsors:BodyHealth: Use code LYON20 to get 20% off your first order https://www.bodyhealthaffiliates.com/73L4QL3/7XDN2/BON CHARGE Holiday Sale https://boncharge.com for 25% off Pique 20% off for life: https://Piquelife.com/DRLYONFind Ben Rein at: Website: https://www.benrein.com/Instagram: https://www.instagram.com/dr.benrein/#TikTok: https://www.tiktok.com/@dr.benrein?lang=enFacebook:

EPISODE DESCRIPTION:Libby Amber Shayo didn't just survive the pandemic—she branded it. Armed with a bun, a New York accent, and enough generational trauma to sell out a two-drink-minimum crowd, she turned her Jewish mom impressions into the viral sensation known as Sheryl Cohen. What started as one-off TikToks became a career in full technicolor: stand-up, sketch, podcasting, and Jewish community building.We covered everything. Jew camp lore. COVID courtship. Hannah Montana. Holocaust comedy. Dating app postmortems. And the raw, relentless grief that comes with being Jewish online in 2025. Libby's alter ego lets her say the quiet parts out loud, but the real Libby? She's got receipts, range, and a righteous sense of purpose.If you're burnt out on algorithm-friendly “influencers,” meet a creator who actually stands for something. She doesn't flinch. She doesn't filter. And she damn well earned her platform.This is the most Jewish episode I've ever recorded. And yes, there will be guilt.RELATED LINKSLibby's Website: https://libbyambershayo.comInstagram: https://www.instagram.com/libbyambershayoTikTok: https://www.tiktok.com/@libbyambershayoLinkedIn: https://www.linkedin.com/in/libby-walkerSchmuckboys Podcast: https://jewishjournal.com/podcasts/schmuckboysForbes Feature: Modern Mrs. Maisel Vibes https://www.forbes.com/sites/joshweissMedium Profile: https://medium.com/@libbyambershayoFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform.For guest suggestions or sponsorship, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Drs. Kat Talcott and Sarwar Zahid join to discuss the December 2025 edition of Retinal Physician, including an overview of TKIs for retinal disease, the fluorinated gas and sustainability question, best practices for research clinical trial sites, and fellowship selection advice.

Just 4 simple lifestyle measures deliver 9 additional years of disease-free healthspan; Study underscores protein's role in staving off cancer, heart disease, and death; CoQ10 scores vs. neurodegeneration; Urolithin A (Mitopure®️) found to support athletic performance, immune function; Why you should ignore some influencers' advice to avoid fish oil. 

Send us a textDr. Koren joins Kevin Geddings to report live from the American Heart Association meeting in New Orleans with fresh results on LDL lowering, prevention, and the future of gene editing for cholesterol. They discuss the excitement of big meetings like the AHA and how results can even surprise the investigators that were working on a study.Note: Dr. Koren refers to CRISPR Therapeutics, a company developing gene-based cholesterol lowering technologies. CRISPR-Cas9 is also the general name of a gene editing technique.Be a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on Apple PodcastsWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramX (Formerly Twitter)LinkedInWant to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

Send us a textCould exercise be just what the doctor ordered for recovery during chemotherapy? In this episode of “The UMB Pulse,” explore this novel approach to cancer recovery with Ian Kleckner, PhD, MPH, associate professor at the University of Maryland School of Nursing and director of the SYNAPSE Center. Kleckner shares how exercise can alleviate symptoms of chemotherapy-induced peripheral neuropathy and improve the quality of life for cancer survivors. Through his research, Kleckner investigates how movement can reduce inflammation, enhance brain and body coordination, and empower patients to reclaim their lives. Chapter Markers 00:00 – Introduction 00:00:17 – Cancer Treatment & Neuropathy 00:01:37 – Guest Introduction: Dr. Ian Kleckner 00:05:06 – Understanding Neuropathy 00:09:38 – Research Findings: Brain & Exercise 00:13:33 – Exercise Intervention & Clinical Trials 00:19:08 – Practical Advice & Takeaways 00:23:31 – Conclusion & CreditsListen to The UMB Pulse on Apple, Spotify, Amazon Music, and wherever you like to listen. The UMB Pulse is also now on YouTube.Visit our website at umaryland.edu/pulse or email us at umbpulse@umaryland.edu.

Kidney Week has begun. Listen as Hiddo Jan L. Heerspink, PhD, Julie R. Ingelfinger, MD, and Richard A. Lafayette, MD, explore the impact this year's late-breaking clinical trials will have on nephrology.

Kidney Week has begun. Listen as Hiddo Jan L. Heerspink, PhD, Julie R. Ingelfinger, MD, and Richard A. Lafayette, MD, explore the impact this year's late-breaking clinical trials will have on nephrology.

When the system kills a $2.4 million study on Black maternal health with one Friday afternoon email, the message is loud and clear: stop asking questions that make power uncomfortable. Dr. Jaime Slaughter-Acey, an epidemiologist at UNC, built a groundbreaking project called LIFE-2 to uncover how racism and stress shape the biology of pregnancy. It was science rooted in community, humanity, and truth. Then NIH pulled the plug, calling her work “DEI.” Jaime didn't quit. She fought back, turning her grief into art and her outrage into action. This episode is about the cost of integrity, the politics of science, and what happens when researchers refuse to stay silent.RELATED LINKS• The Guardian article• NIH Grant• Jaime's LinkedIn Post• Jaime's Website• Faculty PageFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this episode, Jonathan Sackier speaks with Brian Rini, Chief of Clinical Trials at Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, USA, and an internationally known leader in genitourinary oncology. The discussion explores the evolution of kidney cancer treatment, highlighting breakthroughs in immunotherapy, targeted therapy, and precision oncology. Rini shares insights from landmark clinical trials, his passion for translational research, and the challenges of broadening trial access. He also reflects on the future of the field, including the role of artificial intelligence, biomarker-driven strategies, and his hopes for advancing patient outcomes worldwide.  Timestamps:    00:00 – Introduction  01:10 – Key insights into kidney cancer  03:50 – Brian's career journey  07:40 – One piece of career advice   10:40 – Diagnosis of kidney cancer   12:04 – Treatment landscape for kidney cancer  17:00 – Landmark trials in renal cell carcinoma   19:18 – Precision-based approach in trial design and selection  23:40 – Translational research  26:35 – Clinical trial recruitment  30:25 – Diversity in kidney cancer research  32:27 – ESMO 2025 highlights  35:00 – Potential of AI in trial design and recruitment  36:43 – Uncovered areas for research  38:12 – Brian's three wishes for healthcare   

EPISODE DESCRIPTIONAllison Applebaum was supposed to become a concert pianist. She chose ballet instead. Then 9/11 hit, and she ran straight into a psych ward—on purpose. What followed was one of the most quietly revolutionary acts in modern medicine: founding the country's first mental health clinic for caregivers. Because the system had decided that if you love someone dying, you don't get care. You get to wait in the hallway.She's a clinical psychologist. A former dancer. A daughter who sat next to her dad—legendary arranger of Stand By Me—through every ER visit, hallway wait, and impossible choice. Now she's training hospitals across the country to finally treat caregivers like patients. With names. With needs. With billing codes.We talked about music, grief, psycho-oncology, the real cost of invisible labor, and why no one gives a shit about the person driving you to chemo. This one's for the ones in the waiting room.RELATED LINKSAllisonApplebaum.comStand By Me – The BookLinkedInInstagramThe Elbaum Family Center for Caregiving at Mount SinaiFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Taking a photo of your food and getting an accurate carb count seemed like a pipe dream just a few years ago, but this week's guest says it's here. Snaq wants to help you get nutritional info, and then see how that food actually affects blood glucose, thanks to integrations with CGMs, insulin pumps, and activity trackers. Snaq founder Aurelian Briner explains how his wife's type 1 diagnosis inspired the company, how it all works (and who owns the data), and what's next. Learn more about Snaq here Clinical Trial with Snaq here This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom  Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.

This week on Taking The Pulse, Heather and Seth record at the NCLifeSci 2025 Annual Meeting with Sophia McLeod, Advocacy Advisor at ACRO, or the Association of Clinical Research Organizations. Sophia shares how ACRO is working with Congress and the FDA to shape the future of clinical trials, advocating for safe, ethical, and high-quality research so patients can benefit from new treatment and therapies. We explore the challenges of regulatory uncertainty, the importance of trust and transparency in AI adoption, and how ACRO's member organizations are already using AI to accelerate patient recruitment and improve trial outcomes. Listen now!

Send us a textDr. Michael Koren joins Kevin Geddings to discuss the current state of COVID vaccines and research. The cardiologist weighs the real risks and benefits of COVID vaccines, focusing on who may need protection the most and who might be able to skip this year's booster. Dr. Koren also talks about the new prescription mandate for COVID vaccines, and how joining a clinical trial may help some people clear that burden more easily.Be a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on Apple PodcastsWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramX (Formerly Twitter)LinkedInWant to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

For TriloTalk episode 38, Lisa Chamberlain James, Senior Partner at Trilogy, and Sudipta Chakraborty, Head of Literacy & Plain Language Center of Excellence at Biogen, talk about how to use AI in the creation of lay summaries of clinical trial results. Scalability, change management, prompting, biases, realistic attitudes, and human involvement are all touched on so listen up! 

On this episode Gil Bashe and Gregg Masters sit with Joseph Dustin, founder and principal of Dauntless E-Clinical Strategies and former Medidata executive. Dustin recounts his two-decade journey transforming clinical trials—from the dawn of electronic data capture to the age of AI-driven design—and reflects on lessons learned from the late Medidata co-founder Glenn de Vries. They explore how empathy, creativity, and human connection drive innovation in clinical research—especially as artificial intelligence reshapes trial design, digital biomarkers, and decentralized models. Dustin argues that technology succeeds only when it amplifies human insight rather than replaces it. Recorded ahead of the CNS Summit 2025, the conversation highlights community, mentorship, and the “game-on” mindset that propels the next generation of biotech and mid-market innovators. To stream our Station live 24/7 visit www.HealthcareNOWRadio.com or ask your Smart Device to “….Play Healthcare NOW Radio”. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen

In this powerful and eye-opening conversation, Leanne Woehlke sits down with Dr. Ruchir Gupta, a double board-certified pain specialist and founder of Mountain View Headache and Spine Institute, to explore the evolving world of chronic pain treatment and clinical research.Dr. Gupta shares his journey from anesthesiology into chronic pain medicine and research, highlighting why traditional approaches often fail and how emerging therapies like ketamine infusions and stem cell treatments offer new hope. Together, they discuss the importance of changing the language around "experimental" medicine, improving access to clinical trials, and educating patients and physicians about cutting-edge but underutilized treatments.They also tackle:The broken incentives in insurance-driven medicineHow to ethically introduce new treatments to patientsThe power of AI and EMRs in revolutionizing clinical trial recruitmentRebuilding trust in the medical system through transparency and educationThis episode is a must-listen for healthcare professionals, clinical researchers, and patients seeking alternatives to outdated treatments and a deeper understanding of how clinical research can drive real change in patient care.Dr Ruchir Gupta:Dr. Ruchir Gupta is a board-certified pain specialist and anesthesiologist with advanced training in chronic pain management from the Mayo Clinic's Alix School of Medicine in Arizona. A New York native, he completed medical school at Upstate Medical University in Syracuse and his anesthesiology residency at New York Medical College – St. Vincent's Hospital in Manhattan.With over 20 peer-reviewed publications and two medical textbooks to his name, Dr. Gupta blends cutting-edge Western medicine with holistic, nature-based therapies. His areas of expertise include interventional pain management, IV infusion therapy, bone marrow concentrate procedures, and regenerative orthopedics.Dr. Gupta is a member of several leading professional societies, including the American Society of Pain and Neuroscience and the American Headache Society. He currently practices in Mesa and Phoenix, Arizona, where he is also part of the elite Regenexx network of interventional orthopedic physicians.To connect with Dr Gupta:LinkedIn: https://www.linkedin.com/in/ruchir-gupta-3187326b/https://mountainviewheadacheandspine.com/

EPISODE DESCRIPTIONRebecca V. Nellis never meant to run a nonprofit. She just never left. Twenty years later, she's still helming Cancer and Careers after a Craigslist maternity-leave temp job turned into a lifelong mission.In this 60-minute doubleheader, we cover everything from theater nerdom and improv rules for surviving bureaucracy, to hanging up on Jon Bon Jovi, to navigating cancer while working—or working while surviving cancer. Same thing.Rebecca's path is part Second City, part Prague hostel, part Upper East Side grant writer, and somehow all of that makes perfect sense. She breaks down how theater kids become nonprofit lifers, how “sample sale feminism” helped shape a cancer rights org, and how you know when the work is finally worth staying for.Also: Cleavon Little. Tap Dance Kid. 42 countries. And one extremely awkward moment involving a room full of women's handbags and one very confused Matthew.If you've ever had to hide your diagnosis to keep a job—or wanted to burn the whole HR system down—this one's for you.RELATED LINKSCancer and CareersRebecca Nellis on LinkedIn2024 Cancer and Careers Research ReportWorking with Cancer Pledge (Publicis)CEW FoundationI'm Not Rappaport – Broadway InfoFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship opportunities, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Today's guest is Scott Bradley, VP of AI and Innovation at Novartis. As the eighth largest pharmaceutical company in the world by revenue, Novartis' medicines reach millions of people worldwide. Their focus on the discovery and development of novel, breakthrough treatments sees them reimagining not just the delivery of said treatments, but the practice of medicine at large. Scott joins Emerj Editorial Director Matthew DeMello to examine how artificial intelligence is transforming trial design, operations, and patient engagement — while also reshaping industry trust and accountability. Want to share your AI adoption story with executive peers? Click emerj.com/expert2 for more information and to be a potential future guest on the ‘AI in Business' podcast!

While we're making progress in TREATING cancer, worldwide cancer INCIDENCE is soaring, especially among young people; New guidelines for colon cancer screening urge earlier start at age 45; Rates of peanut allergy are declining as more parents follow revised advice to introduce nuts earlier to kids; What's with all the buzz about methylene blue? Legalization and stronger pot are creating an epidemic of ER visits for uncontrolled vomiting, debilitating abdominal pain; New smart toilet gives you a report card on your poop; When Zoloft doesn't work for anxiety.

Send us a textNebulized nitroglycerin as an adjuvant drug in management of persistent pulmonary hypertension of newborns: a randomized controlled trial.Farag MM, Ghazal HAE, Abdel-Mohsen AM, Rezk MA.Eur J Pediatr. 2025 Sep 1;184(9):586. doi: 10.1007/s00431-025-06381-5.PMID: 40888971 Free PMC article. Clinical Trial.Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!